Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidai aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study

Clinical Cancer Research

Volumn 3, Issue 7, 1997, Pages 1101-1108

  Johannessen, Dag Clement ^b   Engan, Terje ^c   Di Salle, Enrico ^d   Zurlo, Maria Grazia ^d   Paolini, Jolanda ^d   Ornati, Giorgio ^d   Piscitelli, Gabriella ^d   Kvinnsland, Stener ^a,c   Lønning, Per Eystein ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXEMESTANE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; ESTROGEN RELEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONE INHIBITION; HOT FLUSH; HUMAN; HYPERTRICHOSIS; MYALGIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; ALPROSTADIL; ANDROGENS; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTRONE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; POSTMENOPAUSE;

EID: 0030748661     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Lønning, P. H., and Kvinnsland, S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs, 35: 685-710, 1988.
2. Lønning, P. E., and Lien, E. Mechanisms of action of endocrine treatment in breast cancer. Crit. Rev. Oncol. Haematol., 21: 158-193, 1995.
3. Jonat, W., Howell, A., Blomqvist, C., Eiermann, W., Winblad, G., Tyrrell, C., Mauriac, L., Roche, H., Lundgren, S., Hellmund, R., and Azab, M. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer, 32A: 404-412, 1996.
4. Raats, J. I., Falkson, G., and Falkson, H. C. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J. Clin. Oncol., 10: 111-116, 1992.
5. Johnston, S. R. D., Smith, I. E., Doody, D., Jacobs, S., Robertshaw, H., and Dowsett, M. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res., 54: 5875-5881, 1994.
6. Iveson, T. J., Smith, I. E., Ahern, J., Smithers, D. A., Trunet, P. F., and Dowsett, M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res., 53: 266-270, 1993.
7. Goss, P. E., Powles, T. J., Dowsett, M., Hutchison, G., Brodie, A. M. H., Gazet, J-C., and Coombes, R. C. Treatment of advanced breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report. Cancer Res., 46: 4823-4826, 1986.
8. Dowsett, M., Mehta, A., King, N., Smith, I. E., Powles, T. J., Stein, R. C., and Coombes, R. C. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Eur. J. Cancer, 28: 415-420, 1992.
9. Dowsett, M., Cunningham, D. C., Stein, R. C., Evans, S., Dehennin, L., Hedley, A., and Coombes, R. C. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res., 49: 1306-1312, 1989.
10. Miller, W. R. Aromatase inhibition in the treatment of advanced breast cancer. Cancer Treat. Rev., 16: 83-93, 1989.
11. Brodie, A. M. H., Garrett, W. M., Hendrickson, J. R., Tsai-Morris, C-H., Marcotte, P. A., and Robinson, C. H. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids, 38: 693-702, 1981.
12. Geisler, J., Johannessen, D. C., Anker, G., and Lønning, P. E. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: Clinical and endocrine effects. Eur. J. Cancer, 32A: 789-792, 1996.
13. Murray, R., and Pitt, P. Aromatase inhibition with 4-OH androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res. Treat., 35: 249-253, 1995.
14. di Salle, E., Briatico, G., Giudice, D., Ornati, G., Zaccheo, T., Buzzetti, F., Nesi, M., and Panzeri, A. Novel aromatase and 5α-reductase inhibitors. J. Steroid Biochem. Mol. Biol., 49: 289-294, 1994.
15. di Salle, E., Giudici, D., Briatico, G., and Ornati, G. Novel irreversible aromatase inhibitors. Ann. NY Acad. Sci., 595: 357-367, 1990.
16. Zaccheo, T., and di Salle, E. Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone. Cancer Chemother. Pharmacol., 25: 95-98, 1989.
17. Evans, T. R. J., di Salle, E., Ornati, G., Lassus, M., Benedetti, M. S., Pianezzola, E., and Coombes, R. C. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res., 52: 5933-5939, 1992.
18. Lønning, P. E., Helle, S. I., Johannessen, D. C., Adlercreutz, H., Lien, E. A., Tally, M., Ekse, D., Fotsis, T., Anker, G. B., and Hall, K. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clin. Endocrinol., 42: 23-30, 1995.
19. Zilembo, N., Noberasco, C., Bajetta, E., Martinetti, A., Mariani, L., Orefice, S., Buzzoni, R., Bartolomeo, M. D., Leo, A. D., Laffranchi, A., and di Salle, E. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br. J. Cancer, 72: 1007-1012, 1995.
20. Cocchiara, G., Allievi, C., Berardi, A., Zugnoni, P., Benedetti, M. S., and Dosiert, P. Urinary metabolism of exemestane, a new aromatase inhibitor, in rat, dog, monkey and human volunteers. J. Endocrinol. Invest., 17 (Suppl. 1): 78, 1994.
21. Demers, L. M. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res. Treat., 30: 95-102, 1994.
22. Geisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P. O., and Lønning, P. E. Influence of anastrozole (arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer, 74: 1286-1291, 1996.
23. Dowsett, M., Goss, P. E., Powles, T. J., Hutehinson, G., Brodie, A. M. H., Jeffcoate, S. L., and Coombes, R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res., 47: 1957-1961, 1987.
24. Zaccheo, T., Giudici, D., Ornati, G., Panzeri, A., and di Salle, E. Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours. Eur. J. Cancer, 27: 1145-1150, 1991.
25. Edmunds, S. E. J., Stubbs, A. P., Santos, A. A., and Wilkinson, M. L. Estrogen and androgen regulation of sex hormone binding globulin secretion by a human liver cell line. J. Steroid Biochem. Mol. Biol., 37: 733-739, 1990.
26. Adlercreutz, H., Mousavi, Y., Clark, J., Hockerstedt, K., Hämäläinen, E., Wähälä, K., Mäkelä, T., and Hase, T. Dietary phytoestrogens and cancer: in vitro and in vivo studies. J. Steroid Biochem. Mol. Biol., 41: 331-337, 1992.
27. Giudici, D., Ornati, G., Briatico, G., Buzzetti, F., Lombardi, P., and di Salle, E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J. Steroid Biochem., 30: 391-394, 1988.
28. di Salle, E., Giudici, D., Ornati, G., Briatico, G., D'Alessio, R., Villa, V., and Lombardi, P. 4-Aminoandrostenedione derivatives, a novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione. J. Steroid Biochem. Mol. Biol., 37: 369-374, 1990.